Actoxumab-Anti-C-difficile-Toxin-A-Recombinant-Antibody-DataSheet-生命科学试剂-MCE

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEActoxumabCat.No.:HY-P99277CASNo.:1245634-25-6Synonyms:Anti-C.difficileToxinARecombinantAntibody作⽤靶点:Others作⽤通路:Others储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性Actoxumab⼀种抗艰难梭毒素A(C.difficiletoxinA)的抗毒素抗体，能够靶向并破坏TcdA。Actoxumab能够防⽌可以防⽌肠道壁的损伤和与艰难梭有关的炎症反应。Actoxumab与靶向TcdB的Bezlotoxumab(HY-P9929)表现出良好的协同作⽤。体外研究Actoxumab(10mg/kgWTorN297Qmutant(N297Q)actoxumab-bezlotoxumab;2hplus24h)significantlyinhibitscellroundingactivityinVerocellsunder2ng/mLTcdAtreatment[1].体内研究Actoxumab(0.1-10mg/kgor50mg/kg;i.p.;singledose)showsprotectiveeffectinmultiplemurinemodelsofclostridiumdifficileinfection(CDI),includingsystemicandlocal(gut)toxinchallengemodels,aswellasprimaryandrecurrentmodelsofinfectioninmice[1].ActoxumabshowsasynergywithBezlotoxumab,and(combinationdosageof3,30,300μg/mouse;i.p.;singledose)preventsbothepithelialdamageandinflammatorydisease[1].AnimalModel:MurineC.difficileinfectionmodelinCD1andC57BL/6mice(6-8weeksold)[1]Dosage:Combinationdosageof3,30,300μg/mouse;or~0.1,1,and10mg/kgAdministration:Intraperitonealinjection;singledose;1hourbefore25ngTcdAor25ngTcdBchallengeResult:ProtectedwithBezlotoxumab,againstsystemicandintestinaltoxinchallengeinmice.AnimalModel:IlealloopmodelinCD1andC57BL/6mice(6-8weeksold)[1]Dosage:50mg/kg;orcombinedwith50mg/kgBezlotoxumab1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEAdministration:Intraperitonealinjection;singledoseResult:Significantlyreducedfluidaccumulationintoxin-challengedmice(109.4mg/cm).REFERENCES[1].YangZ,etal.MechanismsofprotectionagainstClostridiumdifficileinfectionbythemonoclonalantitoxinantibodiesactoxumabandbezlotoxumab.InfectImmun.2015Feb;83(2):822-31.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:4